Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Characterization of CB1 Receptors Using [11-C]OMAR in OUD
NCT07800520Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Oct 2026
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of [11C]OMAR in opioid use disorder (OUD) (2 arms), sponsored by Yale University. Primary endpoints: Cannabinoid Receptor 1 Availability at 7 days, Beck Depression Inventory at 90 days and 3 more. Started Oct 2026; status: recruiting.
02
Drugs
[11C]OMAR
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07800520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800520.